Primary source: TGA Safety Alerts - Compliance and enforcement
Infringement notices have been issued for non-compliance with regulations regarding the importation of melatonin.
These infringement notices highlight the TGA's enforcement actions to uphold compliance related to product imports, which impacts overall operational practices in the industry.
Ensure compliance checks are reinforced in the inspection readiness processes to account for potential non-compliance surrounding product imports.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Ensure compliance checks are reinforced in the inspection readiness processes to account for potential non-compliance surrounding product imports.
The Therapeutic Goods Administration (TGA) of Australia has issued infringement notices totaling $71,000 to a company and several pharmacists for importing melatonin unlawfully.
What changed: Infringement notices have been issued for non-compliance with regulations regarding the importation of melatonin.
Why it matters: These infringement notices highlight the TGA's enforcement actions to uphold compliance related to product imports, which impacts overall operational practices in the industry.
Practical implication: Ensure compliance checks are reinforced in the inspection readiness processes to account for potential non-compliance surrounding product imports.
Published from the regulator source ingestion pipeline after PV impact triage.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
